Achilles Therapeutics (ACHL) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Achilles Therapeutics has halted its TIL-based cNeT therapy development and is closing its CHIRON and THETIS clinical trials, shifting focus to evaluate strategic alternatives, including mergers or sales, with the aid of BofA Securities. The company, with a strong cash position of $95.1 million, is committed to reducing costs and maximizing shareholder value by leveraging its assets and proprietary technology in cancer treatment. Despite the strategic shift, Achilles aims to continue advancing treatments for cancer patients using clonal neoantigen targeting.
For further insights into ACHL stock, check out TipRanks’ Stock Analysis page.